Objective: We studied the effects of the transient activation of PTH/PTHrP signaling during the repair of 5-mm-diameter full-thickness defects of articular cartilage in the rabbit.
Introduction
Cartilage is a typical avascular tissue and thus has a very limited capacity for regenerative repair. Full-thickness defects that penetrate articular cartilage and subchondral bone extending into marrow cavity undergo a repair process that eventually fills the defect cavities with fibrous, fibrocartilaginous, or hyaline cartilaginous tissue, depending on the location and size of injury 1, 2 . In a mature rabbit model, no chondrogenic repair response occurs for large cylindrical defects (≥ 5 mm in diameter) created in the femoral trochlea. In addition, only fibrous tissue has been shown to fill these defect cavities 3 . In contrast, smaller cylindrical defects (≤ 3 mm in diameter) are spontaneously repaired with regenerated hyaline cartilage 3 . Bone marrow derived chondroprogenitor cells have an essential role in the chondrogenic repair of the full-thickness defects of articular cartilage [2] [3] [4] .
Various bioactive molecules, such as growth/differentiation factors and hormones, participate in the regulation of repair response in the defects 5 . Fibroblast growth factor-2 (FGF-2) also plays an important role in the induction of the chondrogenic repair response in cartilage defects by stimulating the mobilization and recruitment of proliferating chondroprogenitor cells into the defect cavities, resulting in the resurfacing the 5-mm-diameter defects via the regeneration of hyaline cartilage 4, 6, 7 .
Hence, size limitations to the chondrogenic repair response in these types of cartilage defects can be alleviated by the addition of exogenous FGF-2 4 . When endogenous FGF-2 activity is neutralized by monoclonal antibodies, no chondrogenic repair response occurs even in the 3-mm-diameter defects, which are filled and resurfaced by fibrous tissue only 3 .
The activation of parathyroid hormone (PTH)/PTH-related peptide (PTHrP) 5 signaling inhibits the differentiation of chondroprogenitor cells that are recruited to reparative tissue in cartilage defects 8 . The local administration of human PTH completely disrupts the differentiation of chondroprogenitor cells in 3-mm-dimeter defects. There have been no adverse effects detected in the preceding steps for chondrogenesis upon exposure to PTH, i.e. the migration and proliferation of PTH/PTHrP receptor-positive chondroprogenitor cells. Chondrogenesis resumes when the defects are released from inhibitory PTH/PTHrP signaling during the early phase of repair at 2 weeks post-injury 9 . Mesenchymal cells that migrate to the site of repair have been found to be chondrogenesis-competent for only a limited time-span of around 2
weeks, but they lose their chondrogenic capacity after prolonged PTH treatment for 4
weeks. Most of the cells in the reparative tissue are PTH/PTHrP receptor-negative. Thus, 3-mm-diameter small defects continuously treated with PTH for 4 weeks are never covered with cartilage 9 .
In our present study, we examined the effects of the transient activation and release from PTH/PTHrP signaling upon the repair response in 5-mm-diameter large full-thickness defects of articular cartilage in the rabbit. Our results indicate that the intermittent administration of PTH successfully induces the chondrogenic repair response in these defects and will be beneficial for the regenerative repair of large full-thickness defects of articular cartilage.
Materials and methods

Creation of full-thickness defects of articular cartilage in rabbits
Male adolescent Japanese white rabbits (n = 55), weighing 3-3.4 kg, were anaesthetized with sodium pentobarbital (30 mg/kg body weight intravenously). The right knee joint was then opened using a medial parapatellar approach under sterile conditions and the patella was dislocated laterally to expose the articular surface of the femoral trochlea. Full-thickness defects (5 mm in diameter; 4 mm in depth) were created in the weight-bearing area of the femoral trochlea with a hand-drill equipped with a 5-mm diameter drill-bit, as described previously 3, 8 . All animals were allowed to walk freely without a splint. Our research protocol was approved by the animal ethics committee of Kumamoto University School of Medicine, and animal care and experimental procedures were conducted in accordance with institutional guidelines (http://card.medic.kumamoto-u.ac.jp/card/japanese/kisoku/kisoku.html).
Administration of hPTH(1-84)
Recombinant human parathyroid hormone 1-84 (hPTH(1-84)) was expressed and purified from Escherichia coli by high-performance liquid chromatography using a cleavable fusion protein strategy as previously described 10 . Purified hPTH prepared in this way was supplied by Chugai Pharmaceuticals (Tokyo, Japan) for the present study. The animals were fitted with an osmotic pump (Alzet, Model 2002, Alza
Corp., Palo Alto, CA) connected to silastic medical grade tubing (0.75 mm inside diameter/1.45 mm outside diameter). A 5-mm-long piece of tubing was then introduced into the articular knee cavity through the articular capsule. An osmotic pump was then 7 placed subcutaneously into the hind region of the leg and the articular capsule and skin were closed independently with 4-0 nylon sutures 3, 8 .
Fifty-five rabbits were given 5-mm-diameter defects and then divided into three experimental groups; one group was treated with PTH continuously for 2 weeks after injury (the continuous PTH group, n = 15), one group was treated with PTH intermittently for 2 weeks after injury (the intermittent PTH group, n = 15), and we analyzed an untreated control group (n = 20) which received saline alone for 2 weeks.
In some experiments, additional untreated control rabbits (n = 5) which received saline for 1 week were sacrificed and subjected to histological analysis at 1 week post-injury.
PTH was dissolved in sterile saline at a concentration of 50 g/ml. The PTH solution was used in the continuous and intermittent PTH group. For animals in the continuous PTH group, the osmotic pumps were filled with 200 l of sterile saline containing human recombinant PTH (50 g/ml) and had a nominal pumping rate of 0.5 l/h for 2 weeks. For animals in the intermittent PTH group, the osmotic pumps filled with sterile saline were connected to a length of tubing that had been precharged with the intermittent administration program. The program consisted of alternating segments of 5 l PTH (50 g/ml) solution and 5 l sterile saline interrupted by 1 l air bubbles. As saline from the pump gradually displaced the contents of the tubing, precharged PTH solution or sterile saline were alternatively discharged from the opposite end of the tubing. This pumping system results in the administration of the hormone solution for 10 hours with a 14-hour-interval. The animals were thus given an intermittent administration of PTH for two weeks post-injury. In all experimental group, the implanted osmotic pump and tubing were removed at 2 weeks after creation of the defects.
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Histological and immunohistochemical analyses
Five animals from each study group were sacrificed at each time point with an overdose of sodium pentobarbital. The distal portion of each femur was then fixed in 4% paraformaldehyde at room temperature for 1 hour, decalcified with 10% EDTA for 3 weeks and then embedded in paraffin for subsequent histological analysis. To examine the sequential repair processes in each cavity, 5 m transverse sections were cut in the transverse plane. The sequential repair process of each group was histologically analyzed as previously reported 8, 9 . For semi-quantitative analysis of the reparative tissue, the sections were examined in a blind manner by two observers, and were scored according to the modified Pineda scale (Table I) 11 and the O'Driscoll score (Table II) 12 .
The modified Pineda scale used was inversely correlated to the original one so that a better recovery of the articular structure had a higher score. The score ranged from 0 (worst) to 14 (best). For quantification of subchondral bone repair, the cross-sectional area of the subchondral bone in the defects was measured. The section that had the maximum diameter (5 mm) was chosen as the representative section for each animal.
The images were captured as digitized images with a scanner and stored on a personal computer. Both edges of the defect on the surface and a perpendicular (5 mm wide and 4 mm deep) rectangular region (original defect area) were delineated on the digital images, which were processed using Adobe Photoshop 3.0 to exclude cartilage, fibrous tissues and bone marrow. The cross-sectional area of bone within the original defect was determined using National Institutes of Health (NIH) image version 1.6 image analysis software (NIH, Bethesda, MD). The cross-sectional area of the subchondral bone was expressed as the mean and 95% confidence interval of five animals from each experimental group.
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The presence of type II collagen in reparative tissues was examined immunohistochemically using a mouse monoclonal antibody against human type II collagen (Fuji Chemical, Takaoka, Japan) as this antibody cross-reacts with rabbit type II collagen 13 . The paraffin sections were deparaffinized and hydrated, and endogenous peroxidase activity was blocked by 0.5% hydrogen peroxide in methanol, followed by washing with 0.1% bovine serum albumin (BSA) in Tris-buffered saline (TBS). The sections were then treated with 500 U/ml testicular hyaluronidase (Sigma Chemical Co., St Louis, MO) 14 . Non-specific staining was reduced by incubation with horse serum.
The sections were incubated with the primary antibody (dilution 1:100) overnight at 4°C, treated with the Vectastain avidin-biotin-peroxidase complex (ABC) kit (Vector Laboratories, Burlingame, CA), reacted with diaminobenzidine (DAB) solution, and then counterstained with hematoxylin.
The expression of PTH/PTHrP receptor protein in the reparative tissue was examined using a mouse monoclonal antibody raised against the opossum PTH receptor (Berkley antibody Co, Richmond, CA) using the same protocol described above 9 . The specificity and cross-reactivity of the monoclonal antibody to the rabbit PTH receptor were confirmed using the rabbit kidney and growth plate as a positive control [ Fig 
Statistical analysis
Results were expressed as mean and 95% confidence intervals. Statistical significance was estimated using Mann-Whitney's U test. A p value of < 0.05 was considered statistically significant.
Results
Histological features during the repair of articular cartilage defects
Large cylindrical full-thickness articular cartilage defects (5 mm in diameter)
are not resurfaced with hyaline-like cartilage spontaneously, but filled with fibrous tissue only [1] [2] [3] . Control defects treated with saline alone were initially filled with blood clots but contained undifferentiated fibroblast-like cells within 2 weeks [ Fig. 1(A) ].
Although there was no sign of cartilaginous repair in these saline treated defect cavities (Table III) . At 8 weeks, the subchondral bone was almost completely reconstituted (Table III) of PTH administration at 2 weeks post-injury appeared to be smaller than that of the control defects, but similar to that of the control defects at 1 week after injury (Table III) .
This was not statistically significant however.
In the animal groups that had been continuously treated or intermittently treated with PTH for the initial 2 weeks, chondrogenesis was evident in the defect cavities by 4 weeks post-injury. In both groups also, the defects contained similar 
Chondrogenic responses in the defect cavities
In the control cartilage defects treated with saline alone, the expression of PCNA was only found in mesenchymal cells deeply located at the periphery of the defects (near to the subchondral bone surface) at 2 weeks post-injury. Most of the cells filling these saline-treated defects were PCNA-negative. The incidence of PCNA-positive cells was also below 20% on average in the control group (Table IV) and PTH/PTHrP receptor-positive cells were detectable only at the periphery of the defects, many of which were also PCNA-positive. On the other hand, the sustained activation of PTH/PTHrP signaling clearly inhibits the differentiation of chondroprogenitor cells 8, 29 . The continuous local administration of PTH was found previously to completely inhibited cartilage formation, even in the 3-mm-diameter smaller defects and despite an apparent accumulation of proliferating chondroprogenitor cells in the defect cavities during the early stages of repair 8 . Accumulated chondroprogenitor cells remain chondrogenesis competent for at least 2 weeks in the defect cavities, but lose this ability by 4 weeks after the creation of cartilage defects 9 . We thus speculate from these earlier findings and our present experimental setting that reparative tissue has to be released from PTH/PTHrP signaling so that accumulated proliferating chondroprogenitor cells can resume the process of differentiation into chondrocytes.
We observed cartilage formation in both of our PTH-treated animal groups at The anabolic bone effects of PTH administration are well established.
Intermittent PTH administration is also an approved treatment for enhancing bone mass in osteoporosis patients. Recent studies have strongly argued that the Wnt signaling pathway participates in the anabolic effects of PTH on bone formation and fracture repair [30] [31] [32] . However, neither the continuous nor intermittent administration of PTH in our current study produced a statistically significant difference in the time course of subchondral bone reconstitution (Table III) . This suggests that the chondrogenic effects of PTH occur independently of bone formation. In summary, the short-term local administration of PTH shows therapeutic potential as part of a future strategy to regenerate articular cartilage. 
FIG. 2. Histological scores for the reparative 5-mm-diameter cartilage defects treated
according to the modified Pineda scale (Table I) . Values are the means and 95%
confidence interval of the scores from the histological sections of five individual animals. In (A), total histological scores at 2, 4 and 8 weeks post-injury were compared. *Significant difference from control, p < 0.05. To evaluate cartilaginous repair in the induced defects, scores for cell morphology and matrix staining were performed as shown in (B) and (C), respectively. Continuous PTH treated defects showed higher scores compared to the control at 4 weeks (P = 0.0219) in the total score. Intermittent PTH treated defects showed higher scores compared to the control at 4 (P = 0.0219) and 8 weeks (P = 0.0153) in the total score. In the cell morphology, the continuous and the intermittent PTH treated defects showed higher score compared to the control at 8
weeks (control vs continuous PTH treated defect P = 0.0203, vs intermittent PTH treated defect P = 0.0062). In the matrix staining, the both PTH treated defects also showed higher score compared to the control at 8 weeks (control vs continuous PTH treated defect P = 0.0486, vs intermittent PTH treated defect P = 0.0025).
FIG. 3.
Histological scores for the reparative 5-mm-diameter cartilage defects according to the O'Driscoll score (Table II) Photomicrographs were taken of the histologic sections and scanned on a digital scanner. The computerized images were analyzed for cross-sectional area of subchondral bone in the defects using NIH image. Data are represented as a mean and 95%
confidence interval of the mean (n = 5 for each group). There was no significant difference among the groups. All nuclei were counted in a total of 96 fields in the 5-mm-diameter defects at 2 weeks using three section for each animal at a magnification of × 200, as described in Material and Methods. The PCNA-positive and -negative cells were counted in a total of 240 fields in the 5-mm-diameter defects at 2 weeks using three sections for each animal at a magnification of × 400. Data are represented as a mean and 95% confidence interval of the mean. Asterisks (*) signify a statistical significant difference in the incidence of PCNA-positive cells between the control (saline alone) and the continuous PTH treated defects (P = 0.0283) and between the control and the intermittent PTH treated defects (P = 0.009). * * Table IV 
